Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
The company has received approval from DCGI to begin patient enrolment and dosing in the country
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Subscribe To Our Newsletter & Stay Updated
